WuXi AppTec, Laboratory Testing Division’s Post

Looking forward to this webinar! For environmentally conscious scientists, the principle of green analytical toxicology holds great significance. This webinar can empower us to pioneer a path towards responsible scientific practices that prioritize both scientific rigor and environmental sustainability. Dr. Moore's expertise always leads to valuable insights. https://lnkd.in/gQzxheSw

At this year’s Society of Toxicology (SOT) meeting next week, Jasmine Singh, Field Application Scientist, will be co-presenting with Jason McGraw, Charles River Laboratories Reno on Tuesday, March 12, 10:30 am, Room 155 E. Don't miss their session, "Expedited Bioanalysis Timeline Strategy: Using Highly Automated Workflow via the Gyrolab Platform". Talk description: Fully automated ligand binding assay workflow leveraging the Gyrolab and Hamilton platforms has been implemented into a GxP laboratory that allowed for a significant reduction in “time to delivery” of submission-ready bioanalytical data. The increased throughput subsequently allows us to generate robust data more quickly from assay development through sample analysis. https://lnkd.in/e7BZHbdX

Today, we announced year end progress for preclinical development of lead prodrug candidate EB-373. The GLP Safety and Toxicology program of EB-373 is proceeding as planned thus far with favorable results. We expect to finalize all preclinical activities involving EB-373 in the first quarter of 2024 in preparation for a first-in-human clinical trial. To learn more about today’s announcement, click here: https://lnkd.in/e47VrQms #ENVB #MentalHealth #Psilocybin #Biotechnology

Our webinar ‘In Vitro Assessment of Cardiac Risk in Drug Discovery’ enabled attendees to learn how an hiPSC-CM model can help provide clear decision-making data for their project team, avoiding costly issues related to QTc and QRS cardiac liabilities in the clinic. If you missed the presentations by Derek Leishman (VP Translational and Quantitative Toxicology at Eli Lilly and Company) and Steve Jenkinson (VP Drug Discovery and Safety at Metrion) you can request the recording and read the Q&A: https://hubs.la/Q02yXNzr0 #drugdiscovery #ionchannels #cardiacsafety #cardiacrisk #lifesciences

Join Metrion Biosciences for our eagerly awaited forthcoming webinar highlighting the in vitro assessment of cardiac risk within drug discovery. We have two excellent Speakers lined up - sign up below to secure your place! #webinar #ionchannels #drugdiscovery #cardiacsafety #cardiacrisk

✨ $PAB Update Some positive news as we approach the end of the year… Patrys Limited is pleased to announce that its Contract Manufacturing and Development Oganisation (CDMO) has confirmed that a manufacturing slot for the GMP (Good Manufacturing Practice) production of PAT-DX1 will be available in Q1 CY 2024. Additionally, PAB’s GLP toxicology studies are complete, and no safety or tolerability issues were identified. This news paves the way for Patrys to initiate its its first-in-human clinical trial of PAT-DX1 in the second half of CY 2024. Dr James Campbell said: “I am delighted to confirm that, based on the extensive and rigorous investigations by both our CDMO and external manufacturing consultants, we are now able to recommence our manufacturing program of PAT-DX1 in the upcoming quarter. This manufacturing run is expected to produce the drug material that Patrys will use in the Phase 1 clinical trial of PAT-DX1 that is scheduled for the second half of CY2024. ” Read today’s ASX release 👉 https://lnkd.in/gNEAbRMe $PAB #pharma #biotech #innovation #antibodies #clinicaltrial #cancer 

Very often, change… is good. Most sponsors had some adjusting to do in adapting to SEND (Standard for Exchange of Nonclinical Data), but the upsides are real. Here’s one: the use of the SEND standard creates the opportunity for preclinical researchers to access greater pools of specific data and to arrive at better, faster answers to key questions in the early stages of drug development. Accelerating answers for patients depends on these kinds of improvements, and BioCelerate’s SEND Harmonization for Cross-Study Analysis initiative team is ready to share all the details at our upcoming webinar “In Comparable Terms: Driving Efficiencies to Simplify the Ability to Detect Class Effects in Automated Manner through the Use of SEND” on 4 September.  Panelists:    Mark Carfagna, Executive Director of Toxicology, Eli Lilly & Company   William Houser, Senior Principal Scientist, Bristol Myers Squibb   Stephanie Leuenroth Quinn, Associate Director for Pharmacology and Toxicology, FDA    Learn more and register:   https://lnkd.in/ev3a8tWa  

🎙️Derek Leishman, Vice President Translational and Quantitative Toxicology, Eli Lilly and Company, will focus on the opportunities a sponsor now has available to increase the efficiency and effectiveness of QTc assessment by leveraging the ICH S7B core assays. There will also be times when the already conducted core hERG and in vivo assays do not meet the new expected ‘best practice’. The talk will address how gaps in best practice or limitations in tested exposures could be mitigated. Secure your place at the webinar on 16th May: 🔗 https://hubs.la/Q02tVs1W0 #drugdiscovery #ionchannels #cardiacsafety #cardiacrisk #lifesciences

This just in! The BioCelerate SEND (Standard for Exchange of Nonclinical Data) Harmonization initiative team's 3rd manuscript, "Cross Study Analyses of SEND Data: Toxicity Profile Classification," has been published in the Toxicological Sciences journal. Through collaboration with the US FDA CDER (Center for Drug Evaluation and Research), the team is developing analytical approaches to compare toxicological findings from two or more studies using SEND.  And good news! They are collaborating again to share with attendees these SEND findings in our 4 September webinar, "In Comparable Terms: Driving Efficiencies to Simplify the Ability to Detect Class Effects in Automated Manner through the Use of SEND." Panelists include:   Mark Carfagna, Executive Director of Toxicology, Eli Lilly & Company   William Houser, Senior Principal Scientist, Bristol Myers Squibb   Stephanie Leuenroth Quinn, Associate Director for Pharmacology and Toxicology, FDA Read the manuscript and register for the webinar: https://lnkd.in/ev3a8tWa  

How can US biotechs access funding in 2024? Biotechs have expensive R&D cycles involving: 🧿Early Drug Discovery Work - Target Identification, Lead Optimization 🧿Non-Clinical Toxicology 🧿Phase 1, 2, 3 Clinical Trials Currently, the macroeconomic variables make the funding environment VERY challenging. So, in this mini eBook, we're explaining some of our proposed solutions for US biotechs to access funding in 2024. PDF eBook DOWNLOAD below (no email required):